The short answer
Berberine can raise cyclosporine exposure, although the size of the change varies between studies. Have your transplant or prescribing team review it before starting, stopping or changing the dose. Do not use berberine to reduce the amount of cyclosporine you need.
What this answer covers
Oral berberine with systemic oral cyclosporine. The human reports do not fully resolve the cyclosporine formulation or berberine salt, so their results are not interchangeable with every extract or product containing berberine.
- Supplement or preparation
- Berberine
- Medication ingredient
- cyclosporine
What happened in transplant recipients?
In a study of 104 kidney transplant recipients, final cyclosporine trough levels were about 29% higher in the group taking berberine than in the comparison group. A separate assessment in six recipients found about a 35% rise in total exposure. These were monitored treatment settings, not evidence that patients should adjust their own medicine.
Why are some reported percentages misleading?
Cyclosporine levels rose from baseline in both groups of the larger study. The larger increase reported within the berberine group therefore does not represent the difference caused by adding berberine. No significant kidney or liver test change was found during the study, but that does not rule out toxicity in other patients.
Did every study find the same effect?
No. A small healthy-volunteer study found higher exposure with one cyclosporine and berberine regimen, but no significant change with another regimen. Differences in dose, formulation and patient health may matter. The results do not define a berberine amount that can reliably be taken without an interaction.
What should you discuss with your prescriber?
Bring the exact berberine product, its dose and how often you take it. The team may arrange cyclosporine levels and kidney-function tests after a change. No reliable separation interval was established in these studies. Keep taking cyclosporine as prescribed while obtaining advice, and do not change between modified and conventional formulations yourself.
Evidence and practical considerations
Absorption & effectiveness
Berberine can raise cyclosporine exposure, although the size of the change varies between studies. Have your transplant or prescribing team review it before starting, stopping or changing the dose. Do not use berberine to reduce the amount of cyclosporine you need.
- Exact scope
- Oral berberine with systemic oral cyclosporine. The human reports do not fully resolve the cyclosporine formulation or berberine salt, so their results are not interchangeable with every extract or product containing berberine. with Cyclosporine, RxCUI 3008, IN, systemic oral use. Neoral modified microemulsion and conventional Sandimmune are distinguished; neither is automatically dose-equivalent to the other. The Neoral label identifies cyclosporine as the active ingredient and basis of strength. Intravenous reference experiments are identified separately; ophthalmic and topical use are excluded.
- Medication form and route
- oral
- Timing or duration
- Only the durations described in the sources are established; no untested persistence or dose-spacing interval is inferred.
What remains uncertain
- Small pharmacokinetic samples, abstract-only original study access, formulation uncertainty and regimen-dependent results. No personal dose adjustment or validated spacing rule follows from these studies.
Factors that may matter: berberine dose and formulation; cyclosporine formulation; transplant status; other interacting medicines; kidney function.
Read the supporting source summaries
Source 1: regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed systemic oral cyclosporine, including transplant recipients.
Requires clinical and blood-level monitoring, recognizes nephrotoxicity and hyperkalemia, cautions with potassium-containing drugs and explicitly advises avoiding grapefruit and grapefruit juice. Neoral and Sandimmune are not bioequivalent.
How this applies: Direct exact-medication identity and oral monitoring guidance. Pair-specific applicability is restricted to the named food or potassium-containing products; other supplements require their own evidence.
A regulatory label does not quantify each supplement interaction. Botanical effects and absolute event rates cannot be inferred from cyclosporine toxicity alone. Formulation-specific findings must be retained.
Source 2: primary controlled clinical and pharmacokinetic study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 104 renal transplant recipients in a randomized controlled study, 52 per group; a separate pharmacokinetic assessment included six recipients.
Final trough concentrations were 29.3% higher with berberine than without it. In six recipients, cyclosporine AUC increased 34.5%. No significant liver or kidney function change was observed in this monitored study.
How this applies: Direct oral berberine/cyclosporine evidence in renal recipients; no transfer to all berberine-containing plants, enhanced formulations or a personal dose adjustment.
Abstract only. Both groups had substantial increases from baseline, so the 88.9% within-group trough rise is not the controlled treatment effect. Small pharmacokinetic sample, unresolved formulation, and no proof of long-term clinical safety.
Source 3: primary human pharmacokinetic study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Two groups of six healthy male volunteers.
No significant cyclosporine pharmacokinetic change in the higher-dose regimen; the single-dose 3 mg/kg regimen increased AUC by 19.2% and 12-hour concentration from 104 to 123 micrograms/L, without significant peak or half-life changes.
How this applies: Preserves regimen-dependent differences for exact oral cyclosporine and berberine. It cannot establish a predictable effect across products.
Abstract only, very small groups, healthy men rather than transplant recipients, and different exposure regimens. A null result at one dose does not establish a safe berberine dose or spacing interval.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Original studies and regulatory sources checked; a new article prepared with exact formulation and access limits. No independent clinical review is recorded. | |
| Research summary published |
Article revision: f81f70c62f34e509
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.